GPR17 receptor modulators and their therapeutic implications: review of recent patents. (1st February 2019)

• Record Type: Journal Article
• Authors: Marucci, Gabriella; Dal Ben, Diego; Lambertucci, Catia; Martí Navia, Aleix; Spinaci, Andrea; Volpini, Rosaria; Buccioni, Michela
• Is Part Of: Expert opinion on therapeutic patents. Volume 29:Number 2(2019)
• Page Start: 85
• Page End: 95
• Publication Date: 2019-02-01
• Subjects: GPR17 receptor -- leukotrienes -- nucleotides -- oligodendrocytes myelination -- patent; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2019.1568990
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction : The GPR17 receptor, phylogenetically related to both purinergic P2Y and CysLT receptors, is mainly expressed in the CNS and, in general, in organs that can typically undergo ischemic damage. This receptor is involved in various pathologies including stroke, brain and spinal cord trauma, multiple sclerosis and in all diseases characterized by neuronal and myelin dysfunction. Therefore, there is a strong needed to identify molecules capable of binding specifically to GPR17 receptors. Areas covered : The review provides a summary of patents, published between 2009 and 2018, on chemicals and biologics and their clinical use. In this work, information is reported about the representative structures and biological activity of recently developed GPR17 receptor ligands. Expert opinion : The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression. The modulation of this receptor could also be potentially useful in obesity treatment. Unfortunately, so far, there are no compounds under investigation in clinical trials but many researchers and companies are investing in the discovery of future potential GPR17 receptor drugs.